Short Interest in Axsome Therapeutics Inc (AXSM) Grows By 39.2%

Axsome Therapeutics Inc (NASDAQ:AXSM) was the recipient of a significant increase in short interest in October. As of October 31st, there was short interest totalling 1,230,670 shares, an increase of 39.2% from the October 15th total of 883,998 shares. Approximately 7.2% of the company’s stock are sold short. Based on an average trading volume of 447,020 shares, the days-to-cover ratio is currently 2.8 days.

An institutional investor recently raised its position in Axsome Therapeutics stock. Alethea Capital Management LLC grew its position in Axsome Therapeutics Inc (NASDAQ:AXSM) by 132.5% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 270,823 shares of the company’s stock after acquiring an additional 154,323 shares during the period. Axsome Therapeutics comprises 1.5% of Alethea Capital Management LLC’s portfolio, making the stock its 12th largest holding. Alethea Capital Management LLC owned 1.05% of Axsome Therapeutics worth $867,000 at the end of the most recent quarter. 16.70% of the stock is currently owned by hedge funds and other institutional investors.

Shares of AXSM stock opened at $3.87 on Friday. Axsome Therapeutics has a 12 month low of $2.05 and a 12 month high of $5.95. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.26 and a current ratio of 2.26. The company has a market cap of $101.60 million, a price-to-earnings ratio of -3.12 and a beta of -0.51.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings results on Wednesday, August 8th. The company reported ($0.32) EPS for the quarter, meeting the consensus estimate of ($0.32). On average, sell-side analysts anticipate that Axsome Therapeutics will post -1.12 earnings per share for the current fiscal year.

Several equities analysts have commented on the company. ValuEngine upgraded Axsome Therapeutics from a “hold” rating to a “buy” rating in a report on Wednesday. LADENBURG THALM/SH SH set a $5.00 price target on Axsome Therapeutics and gave the company a “buy” rating in a report on Wednesday, October 17th. Zacks Investment Research upgraded Axsome Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 25th. Finally, HC Wainwright set a $10.00 price target on Axsome Therapeutics and gave the company a “buy” rating in a report on Tuesday, October 9th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Axsome Therapeutics presently has a consensus rating of “Buy” and an average price target of $10.10.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was illegally copied and republished in violation of United States and international copyright and trademark laws. The original version of this report can be viewed at

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, is developing novel therapies for central nervous system (CNS) disorders. Its product candidate portfolio includes AXS-05, AXS-09, AXS-02, AXS-07, and AXS-06. AXS-05 is in the Phase III clinical trial in treatment resistant depression and in agitation associated with Alzheimer's disease, as well as in the Phase II clinical trial for smoking cessation.

Featured Story: Terms to Better Understand Call Options

Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply